ClinicalTrials.gg
CompletedNCT02343081Updated Apr 2, 2015Results posted

Bioequivalence Study of Temozolomide in Patients With Primary Tumors of the Central Nervous System

A Phase 4 interventional study of Temozolomide and Temozolomide in Brain Neoplasms, Malignant, Primary, sponsored by Monte Verde SA. Completed at 2 sites in Argentina. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2015-04-02.

Sponsored by Monte Verde SA · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 119 studies testing temozolomide in Brain Neoplasms — 4 open to participants now, 6 under way, 1 of them phase 3. Temozolomide · Brain Neoplasms.

Enrollment
73rd of 109
24 · median 34
Started
2012
with 2 others
Phase 4
Only one
of the 119
Registered
99th of 119
by date

Among the 119 studies testing temozolomide in Brain Neoplasms, this one is the 73rd largest by enrollment of the 109 interventional ones that give a count, is one of 3 that started in 2012, is the only one in phase 4, and was the 99th registered.

Brain Neoplasms

2,441 studies on the registry are indexed under Brain Neoplasms; 541 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

4 of the 119 studies testing temozolomide in Brain Neoplasms are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About temozolomide

Temozolomide: first FDA approval 1999 (TEMODAR), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 425 Brain Neoplasms studies recruiting now, 286 (67%) set no upper age limit and 82 (19%) stop at 75 or younger; 80 take children under 18; 36 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 119 studies testing temozolomide in Brain Neoplasms, or all of them as a file.
02

Study summary

The purpose of this crossover, single-dose, bioequivalence study is to compare the rate and extent of absorption of Temozolomide after the administration of the study product (Dralitem®, Monte Verde S.A.) and the reference product (Temodal®, Schering Plough) in primary Central Nervous System patients.

Read the detailed description

Prospective, randomized, two-period, two treatment, two-way crossover bioequivalence study of two Temozolomide oral formulations (Dralitem vs. Temodal), in primary Central Nervous System tumor patients under fasting conditions. Open label to the patients and investigators and blind to the bioanalytical and clinical laboratories.

Study plan: days -21 to 0 (Recruitment period); days 1 to 5 (Treatment period); days 6 to 21 (Safety surveillance period). Sample size: 24 patients will be randomized. The patients will be administered Temozolomide 200 mg/m2 on the first two days (Dralitem) of the treatment cycle.

They will be admitted to the study clinical site on the evening of day 2. In the morning of day 3 they will be randomized into two groups of equal size. According to the assigned random number, each subject will receive a single oral dose of Temozolomide 200mg/m2 from either Monte Verde Sociedad Anónima (SA) product (Dralitem) or from Schering-Plough product (Temodal). The single dose of 200 mg/m2 will be reached with three different Temozolomide capsule strengths: 20, 100 and 250 mg. Drugs will be administered with 200-240 ml of water in semi-sitting upright position.

The following day (day 4) each subject will receive an oral dose of Temozolomide 200 mg/m2 of the product that did not receive the day before. On days 3 and 4 after drug administration, blood samples will be obtained for pharmacokinetic evaluation. The patient will be discharged from the clinical site on day 4 after completion of sampling for pharmacokinetic analysis. On day 5, all patients will receive Temozolomide 200 mg/m2 (Dralitem).

On days 3 and 4, samples of venous blood will be withdrawn from the forearm vein of each volunteer at the following time points: 0 (pre-dose) and 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0 hours post-dose after each period administration. The washout period between the treatment arms was 10 hours, on days 3 and 4. Samples will be processed according to the validated method MANA (Método Analítico) - PLB (Proyecto Laboratorio Bioanalítico) 004 - TEM (Temozolomide) - 01/01. Measurement of plasma concentration of Temozolomide was performed using High Performance Liquid Chromatography (HPLC) followed by detection by tandem mass spectrometry (MS / MS).

The area under the curve (AUC) and the Cmax levels of the drug vs. time will be obtained for each subject. The resulting values of the logarithmic transformation of these parameters will be used for statistical comparisons (mixed effects ANOVA). The limits of the 90% confidence interval for the ratio of log transformed pharmacokinetic parameters will be calculated. Bioequivalence criteria: each calculated confidence interval should be within the acceptance range from 80.00 to 125.00.

03

Conditions studied

  • Brain Neoplasms, Malignant, Primary

Browse trials for

Keywords

  • brain neoplasm
  • bioequivalence
  • temozolomide
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients with primary malignant tumors of the central nervous system (CNS) excluding subjects with primary CNS lymphoma.
  2. Age> 21 years.
  3. There should be a gap of two weeks between the last surgery and/or radiotherapy procedure and the day of randomization. If the procedure were intrabdominal, the gap should be of four weeks.
  4. Patients with neutrophils> 1.5 x 109 / L and > 100 x 109 / L.
  5. Signed written for participation in the trial.

Exclusion criteria

Exclusion Criteria:

  1. Known to Temozolomide or any other ingredient of the pharmaceutical formulation.
  2. Any situation (eg. vomiting) that may interfere with the absorption of the product under study.
  3. Chemotherapy or biological therapy within four weeks prior to administering the products under study.
  4. Patients who experience any symptoms of toxicity to prior antineoplastic therapies upon administration of the products under study.
  5. Participation in other clinical research studies during the 90 days before the start of this study.
  6. History of alcohol or drugs abuse.
  7. History of severe allergic reactions to any type of antigen.
  8. History of gastrointestinal surgery (except uncomplicated appendectomy, of at least three months old).
  9. Patients whose clinical status would affect the safety of the products under study or interfere with the pharmacokinetic evaluation, at the discretion of the investigator.
  10. Pregnant women or women planning to become pregnant during the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Active comparator
    Temodal

    Temozolomide (Schering-Plough) 200 mg/m2, single oral dose.

    Drug: Temozolomide

  • Experimental
    Dralitem

    Temozolomide (Monte Verde S.A.) 200 mg/m2, single oral dose

    Drug: Temozolomide

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax

    Rate of absorption of Temozolomide (Cmax) will be measured after the oral administration of the test product (Dralitem®, Monte Verde S.A.) or the reference product (Temodal®, Schering-Plough).

    Time frame: 0, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0 hours on Days 3 and 4

  2. AUC0-t

    Extent of absorption of Temozolomide from time (0) to the last quantifiable concentration (t) will be measured after the oral administration of the test product (Dralitem®, Monte Verde S.A.) or the reference product (Temodal®, Schering-Plough)

    Time frame: 0, 0.25, 0.5, 0.75, 1.0, 1.25, 1.75, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0 hours on Days 3 and 4

  3. AUC0-∞

    Extent of absorption of Temozolomide from time (0) to infinity (∞) will be measured after oral administration of the test product (Dralitem®, Monte Verde S.A.) or the reference product (Temodal®, Schering-Plough).

    Time frame: 0, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0 hours on Days 3 and 4

Secondary outcomes

  1. Number of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    AEs and SAEs will be collected from the start of study treatment and until two weeks post last dose. If AEs or SAEs extend in time and are not resolved before the end of the 2-week follow up period, this period shall last until the event/s are resolved.

    Time frame: Up to two weeks post last dose

Other outcomes

  1. Kel

    Rate at which Temozolomide is removed from the body.

    Time frame: 0, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0 hours on Days 3 and 4

  2. T1/2

    Time required for Temozolomide plasma concentration to decrease by 50%

    Time frame: 0, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0 hours on Days 3 and 4

07

Results

Posted Apr 2, 2015

Participant flow

This study enrolled patients with primary tumours of the Central Nervous System (CNS) excluding patients with primary CNS lymphoma, from FLENI Clinical-Surgical Diagnosis and Treatment Institute, Buenos Aires, Argentina. The last patient completed in October 2013.

First Intervention (Day 3)
Participant flow — First Intervention (Day 3)
MilestoneTemodal, Then DralitemDralitem, Then Temodal
Started88
Received intervention88
Completed88
Not completed00
Washout (10 Hours)
Participant flow — Washout (10 Hours)
MilestoneTemodal, Then DralitemDralitem, Then Temodal
Started88
Completed88
Not completed00
Second Intervention (Day 4)
Participant flow — Second Intervention (Day 4)
MilestoneTemodal, Then DralitemDralitem, Then Temodal
Started88
Received intervention88
Completed88
Not completed00

Outcome measures

PrimaryCmax

Rate of absorption of Temozolomide (Cmax) will be measured after the oral administration of the test product (Dralitem®, Monte Verde S.A.) or the reference product (Temodal®, Schering-Plough).

Time frame:
0, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0 hours on Days 3 and 4
Reported as:
Mean · mcg/mL
Cmax
mcg/mLTemodalDralitem
Cmax11.108 ± 2.48610.575 ± 2.805
Statistical analysis
  • Temodal vs Dralitem · ANOVA · p = <0.05 · Cmax: 94.37 · 90% CI 82.69 to 107.69Cmax Test/Reference Ratio
SecondaryNumber of Adverse Events (AEs) and Serious Adverse Events (SAEs)

AEs and SAEs will be collected from the start of study treatment and until two weeks post last dose. If AEs or SAEs extend in time and are not resolved before the end of the 2-week follow up period, this period shall last until the event/s are resolved.

Time frame:
Up to two weeks post last dose

Results for this outcome have not been posted.

Other pre-specifiedKel

Rate at which Temozolomide is removed from the body.

Time frame:
0, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0 hours on Days 3 and 4
Reported as:
Mean · 1/h
Kel
1/hTemodalDralitem
Kel0.3743 ± 0.04510.3691 ± 0.0258
Other pre-specifiedT1/2

Time required for Temozolomide plasma concentration to decrease by 50%

Time frame:
0, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0 hours on Days 3 and 4
Reported as:
Mean · hours
T1/2
hoursTemodalDralitem
T1/21.87 ± 0.201.89 ± 0.13
PrimaryAUC0-t

Extent of absorption of Temozolomide from time (0) to the last quantifiable concentration (t) will be measured after the oral administration of the test product (Dralitem®, Monte Verde S.A.) or the reference product (Temodal®, Schering-Plough)

Time frame:
0, 0.25, 0.5, 0.75, 1.0, 1.25, 1.75, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0 hours on Days 3 and 4
Reported as:
Mean · mcg*h/mL
AUC0-t
mcg*h/mLTemodalDralitem
AUC0-t30.796 ± 3.89331.104 ± 4.019
Statistical analysis
  • Temodal vs Dralitem · ANOVA · p = <0.05 · Auc0-t: 100.99 · 90% CI 97.81 to 104.28AUC0-t Test/Reference Ratio
PrimaryAUC0-∞

Extent of absorption of Temozolomide from time (0) to infinity (∞) will be measured after oral administration of the test product (Dralitem®, Monte Verde S.A.) or the reference product (Temodal®, Schering-Plough).

Time frame:
0, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0 hours on Days 3 and 4
Reported as:
Mean · mcg*h/mL
AUC0-∞
mcg*h/mLTemodalDralitem
AUC0-∞31.817 ± 4.15932.290 ± 4.174
Statistical analysis
  • Temodal vs Dralitem · ANOVA · p = <0.05 · Auc0-inf: 101.53 · 90% CI 98.60 to 104.54AUC0-inf Test/Reference Ratio

Adverse events

Collected over Eighteen days for each arm (Safety Surveillance Period).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Temodal—0/16 (0%)5/16 (31.3%)
Dralitem—0/16 (0%)4/16 (25%)
Most frequent other events
Showing 10 of 16
Most frequent other events
EventTemodalDralitem
Itchy RashSkin and subcutaneous tissue disorders1/160/16
VomitingGastrointestinal disorders1/160/16
GastritisGastrointestinal disorders1/160/16
HyporexiaMetabolism and nutrition disorders1/160/16
Leg EdemaVascular disorders1/160/16
WeaknessNervous system disorders1/160/16
DizzinessNervous system disorders1/160/16
Loss of tasteNervous system disorders1/160/16
AdynamiaNervous system disorders1/160/16
Abdominal PainGastrointestinal disorders1/160/16

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Temodal, Then DralitemDralitem, Then TemodalTotal
Mean53.75 ± 9.3539.75 ± 14.548.44 ± 14.5
Sex: Female, Male
Sex: Female, Male(Participants)Temodal, Then DralitemDralitem, Then TemodalTotal
Female437
Male459
Region of Enrollment
Region of Enrollment(participants)Temodal, Then DralitemDralitem, Then TemodalTotal
Argentina8816
Height
Height(cm)Temodal, Then DralitemDralitem, Then TemodalTotal
Mean169 ± 9.53173.37 ± 8.65170.00 ± 8.00
Weight, Continuous
Weight, Continuous(kg)Temodal, Then DralitemDralitem, Then TemodalTotal
Mean78.87 ± 14.2081.12 ± 10.7879.40 ± 12.00
Body Surface, Continuous
Body Surface, Continuous(m^2)Temodal, Then DralitemDralitem, Then TemodalTotal
Mean1.89 ± 0.221.95 ± 0.161.92 ± 0.19
Body Mass Index
Body Mass Index(kg/m^2)Temodal, Then DralitemDralitem, Then TemodalTotal
Mean26.03 ± 2.0128.46 ± 2.7227.26 ± 2.82
08

Study locations

2 sites
  • FLENI Instituto Clínico-Quirúrgico de Diagnóstico y Tratamiento
    Ciudad Autónoma de Buenos Aires, Buenos Aires C1428AQK, Argentina
  • FLENI Instituto de Rehabilitación y Educación Terapéutica
    Escobar, Buenos Aires B1625XAS, Argentina
09

References and documents

Publications

  • Muggeri A, Vago M, Perez S, Rubio M, Gonzalez C, Magarinos C, Rosenberg M, Costa F, Perez-Lloret S. A Randomized, Open-Label, Two-Way Crossover, Single-Dose Bioequivalence Study of Temozolomide 200 mg/m2 (Dralitem(R) vs. Temodal(R) Capsules) in Patients with Primary Tumors of the Central Nervous System Under Fasting Conditions. Drugs R D. 2017 Sep;17(3):427-434. doi: 10.1007/s40268-017-0199-3. PubMed 28756607 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2015, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2015
First posted
Jan 21, 2015
Start
Jan 2012
Primary completionActual
Oct 2013
CompletionActual
Oct 2013
Results first posted
Apr 2, 2015
Last update
Apr 2, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02343081
Lead sponsor
Monte Verde SA
Collaborators
FLENI Instituto de Rehabilitación y Educación Terapéutica, BA, Argentina., Bioanalytical Unit, Laboratorio Raffo S.A., BA, Argentina., FLENI Multi-Specialty Research Center, BA, Argentina.
Responsible party
Sponsor
First posted
Jan 21, 2015
Start date
Jan 2012
Primary completion
Oct 2013
Completion
Oct 2013
Results posted
Apr 2, 2015
Last update
Apr 2, 2015

Study contacts

Alejandro D Muggeri, Physician
principal investigator · FLENI Instituto Clínico-Quirúrgico de Diagnóstico y Tratamiento

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Temozolomide

Start the discussion